

# ForPatients

by Roche

Solid Tumors

## An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

**Trial Status**  
Recruiting

**Trial Runs In**  
9 Countries

**Trial Identifier**  
NCT04250155 GO41596

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT04250155 GO41596**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---